Addressing Gabapentinoids’ Access Challenges in Saudi Arabia Under New Prescription Regulations: An Expert View
Abstract Gabapentinoids, notably gabapentin and pregabalin, are crucial for managing neuropathic pain in conditions like diabetic neuropathy and specific types of cancer-related pain where opioids are ineffective or undesirable. However, the misuse potential of pregabalin has led to stricter regulat...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-06-01
|
| Series: | Pain and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40122-025-00749-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849334099482771456 |
|---|---|
| author | Khaled K. Aldossari Yazed AlRuthia Ashraf Amir Mohammed Alshurem Hussein Elbadawi Abdullah Kaki |
| author_facet | Khaled K. Aldossari Yazed AlRuthia Ashraf Amir Mohammed Alshurem Hussein Elbadawi Abdullah Kaki |
| author_sort | Khaled K. Aldossari |
| collection | DOAJ |
| description | Abstract Gabapentinoids, notably gabapentin and pregabalin, are crucial for managing neuropathic pain in conditions like diabetic neuropathy and specific types of cancer-related pain where opioids are ineffective or undesirable. However, the misuse potential of pregabalin has led to stricter regulatory controls in many regions, including Saudi Arabia. This expert opinion presents insights from multidisciplinary experts about the impact of these regulations on clinical practice, patient care, and misuse patterns in Saudi Arabia. Pregabalin’s rapid onset of action and probable euphoric effects make it more prone to misuse, especially among younger individuals and those with a history of substance abuse. Gabapentin, in contrast, has a lower abuse potential. Experts discussed the implementation of the National Platform for Narcotic Drugs and Psychotropic Substances (Raqeeb) in Saudi Arabia, a system designed to monitor prescriptions of controlled substances. While effective in curbing over-prescription, it has also introduced unintended challenges. Physicians, fearing scrutiny, often hesitate to prescribe gabapentinoids, leading to delays in treatment and greater reliance on less appropriate alternatives. Moreover, stigma associated with controlled substances has further discouraged patients from seeking treatment, resulting in undertreated pain and a diminished quality of life. This expert opinion highlights the need for a more balanced approach to gabapentinoid regulation. It advocates for improved physician education on the management of neuropathic pain, and public awareness initiatives to curb misuse, reduce stigma, and promote the safe use of medications. Refining the Raqeeb platform could alleviate administrative burdens while ensuring robust oversight. Finally, adopting a risk-stratified approach to prescription would allow close monitoring of high-risk patients for substance abuse while ensuring that low-risk patients maintain access to essential treatments. Addressing these challenges would enable healthcare authorities to prevent abuse while ensuring effective pain relief for patients with legitimate medical needs. |
| format | Article |
| id | doaj-art-64b1a5d66ddd472e80ffa49aedd8c688 |
| institution | Kabale University |
| issn | 2193-8237 2193-651X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Pain and Therapy |
| spelling | doaj-art-64b1a5d66ddd472e80ffa49aedd8c6882025-08-20T03:45:40ZengAdis, Springer HealthcarePain and Therapy2193-82372193-651X2025-06-011441189120110.1007/s40122-025-00749-zAddressing Gabapentinoids’ Access Challenges in Saudi Arabia Under New Prescription Regulations: An Expert ViewKhaled K. Aldossari0Yazed AlRuthia1Ashraf Amir2Mohammed Alshurem3Hussein Elbadawi4Abdullah Kaki5Family and Community Medicine Department, College of Medicine, Prince Sattam Bin Abdulaziz UniversityPharmacoeconomics Research Unit, Department of Clinical Pharmacy, College of Pharmacy, King Saud UniversityFamily Medicine Consultant, Chief Medical Officer, International Medical Centre HospitalNeurology Department, College of Medicine, Imam Abdulrahman Bin Faisal universityDiabetes & Metabolic Unit, My Clinic InternationalConsultant, Department of Anesthesia and Pain Medicine, Alsalama HospitalAbstract Gabapentinoids, notably gabapentin and pregabalin, are crucial for managing neuropathic pain in conditions like diabetic neuropathy and specific types of cancer-related pain where opioids are ineffective or undesirable. However, the misuse potential of pregabalin has led to stricter regulatory controls in many regions, including Saudi Arabia. This expert opinion presents insights from multidisciplinary experts about the impact of these regulations on clinical practice, patient care, and misuse patterns in Saudi Arabia. Pregabalin’s rapid onset of action and probable euphoric effects make it more prone to misuse, especially among younger individuals and those with a history of substance abuse. Gabapentin, in contrast, has a lower abuse potential. Experts discussed the implementation of the National Platform for Narcotic Drugs and Psychotropic Substances (Raqeeb) in Saudi Arabia, a system designed to monitor prescriptions of controlled substances. While effective in curbing over-prescription, it has also introduced unintended challenges. Physicians, fearing scrutiny, often hesitate to prescribe gabapentinoids, leading to delays in treatment and greater reliance on less appropriate alternatives. Moreover, stigma associated with controlled substances has further discouraged patients from seeking treatment, resulting in undertreated pain and a diminished quality of life. This expert opinion highlights the need for a more balanced approach to gabapentinoid regulation. It advocates for improved physician education on the management of neuropathic pain, and public awareness initiatives to curb misuse, reduce stigma, and promote the safe use of medications. Refining the Raqeeb platform could alleviate administrative burdens while ensuring robust oversight. Finally, adopting a risk-stratified approach to prescription would allow close monitoring of high-risk patients for substance abuse while ensuring that low-risk patients maintain access to essential treatments. Addressing these challenges would enable healthcare authorities to prevent abuse while ensuring effective pain relief for patients with legitimate medical needs.https://doi.org/10.1007/s40122-025-00749-zAbuseAddictionEducationDependenceGabapentinoidGabapentin |
| spellingShingle | Khaled K. Aldossari Yazed AlRuthia Ashraf Amir Mohammed Alshurem Hussein Elbadawi Abdullah Kaki Addressing Gabapentinoids’ Access Challenges in Saudi Arabia Under New Prescription Regulations: An Expert View Pain and Therapy Abuse Addiction Education Dependence Gabapentinoid Gabapentin |
| title | Addressing Gabapentinoids’ Access Challenges in Saudi Arabia Under New Prescription Regulations: An Expert View |
| title_full | Addressing Gabapentinoids’ Access Challenges in Saudi Arabia Under New Prescription Regulations: An Expert View |
| title_fullStr | Addressing Gabapentinoids’ Access Challenges in Saudi Arabia Under New Prescription Regulations: An Expert View |
| title_full_unstemmed | Addressing Gabapentinoids’ Access Challenges in Saudi Arabia Under New Prescription Regulations: An Expert View |
| title_short | Addressing Gabapentinoids’ Access Challenges in Saudi Arabia Under New Prescription Regulations: An Expert View |
| title_sort | addressing gabapentinoids access challenges in saudi arabia under new prescription regulations an expert view |
| topic | Abuse Addiction Education Dependence Gabapentinoid Gabapentin |
| url | https://doi.org/10.1007/s40122-025-00749-z |
| work_keys_str_mv | AT khaledkaldossari addressinggabapentinoidsaccesschallengesinsaudiarabiaundernewprescriptionregulationsanexpertview AT yazedalruthia addressinggabapentinoidsaccesschallengesinsaudiarabiaundernewprescriptionregulationsanexpertview AT ashrafamir addressinggabapentinoidsaccesschallengesinsaudiarabiaundernewprescriptionregulationsanexpertview AT mohammedalshurem addressinggabapentinoidsaccesschallengesinsaudiarabiaundernewprescriptionregulationsanexpertview AT husseinelbadawi addressinggabapentinoidsaccesschallengesinsaudiarabiaundernewprescriptionregulationsanexpertview AT abdullahkaki addressinggabapentinoidsaccesschallengesinsaudiarabiaundernewprescriptionregulationsanexpertview |